References
- Jünemann K-P, Hessdorfer E, Unamba-Oparah I, Berse M, Brünjes R, Madersbacher H, (2006). Propiverine hydrochloride immediate and extended release: Comparison of efficacy and tolerability in patients with overactive bladder. Urol Int, 77:334–9.
- Dashevsky A, Kolter K, Bodmeier R. (2004). pH-independent release of a basic drug from pellets coated with the extended release polymer dispersion Kollicoat SR 30 D and the enteric polymer dispersion Kollicoat MAE 30 DP. Eur J Pharm Biopharm, 58:45–9.
- Munday DL. (2003). Film coated pellets containing verapamil hydrochloride: Enhanced dissolution into neutral medium. Drug Dev Ind Pharm, 29:575–83.
- Siepe S. (2005). Strategies to improve oral absorption of weakly basic drug substances by modulating the microenvironmental pH. Doctoral Thesis, University of Genf, Switzerland.
- Thoma K, Zimmer T. (1990). Retardation of weakly basic drugs with diffusion tablets. Int J Pharm, 58:197–202.
- Thoma K, Ziegler I. (1998). The pH-independent release of fenoldopam from pellets with insoluble film coats. Eur J Pharm Biopharm, 46:105–13.
- Venkatesh GM. (1998). Development of controlled release SK&F 82526-J buffer bead formulations with tartaric acid as the buffer. Pharm Dev Tech, 3:477–85.
- Gruber P, Brickl R, Bozler G, Stricker H. (1980) .Neue Dipyridamol-Retardformen und Verfahren zu ihrer Herstellung. EP Patent 0032562, December 17, 1980.
- Gruber P, Schmid J, Lechner H, Bauer E. (1982) .Bromhexin-Retardform und Verfahren zu ihrer Herstellung. EP Patent 0069259, June 18.
- Thoma K, Knott F. (1991). Retardierung schwach basischer Arzneistoffe. Pharm Ind, 53:778–85.
- Warren SJ, MacRae RJ, Melia CD. (1999). Investigation into the effect of weak acid modifiers on improving the release of dipyridamole from extruded spheronised pellets. Proc Intern Symp Control Rel Bioact Mater, 26:6370.
- Guthmann C, Lipp R, Wagner T, Kranz H. (2007). Development of a multiple unit pellet formulation for a weakly basic drug. Drug Dev Ind Pharm, 33:341–9.
- Gramatté T, Gruber P, Güldner P, Heschel M, Pamperin D, Ploen J, (2003) .Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient. W.O. Patent 03/030869, October 8, 2003.
- Kumpugdee M. (2002). Überziehen von pellets mit wässrigen, magensaftresistenten polymerdispersionen in der Wirbelschichtanlage. Doctoral Thesis, University of Hamburg: Germany.
- Siewert M. (1997). FIP Guidelines for dissolution testing of solid oral products. Pharm Ind, 59:760–6.
- Hogan J. (2001). Coating of tablets and multiparticulates. In: Aulton ME, ed. Pharmaceutics: The science of dosage form design. , New York: Churchill Livingstone, 441–8.
- Ozturk AG, Ozturk SS, Palsson BO, Wheatley TA, Dressman JB. (1990). Mechanism of release from pellets coated with an ethylcellulose-based film. J Control Release, 14:203–13.
- Dressman JB, Palsson BO, Ozturk A, Ozturk S. (1994). Mechanisms of release from coated pellets. In: Ghebre-Sellasie I, ed. Multiparticulate oral drug delivery. New York: Marcel Dekker, 285–306.